StockpollyBeta
ChatSearch/
Get AppSign in
Menu
Sign in
CategoryChatSearchBlog
Markets
HeatmapScreener
Tools
P/E Compare
Company
AboutPricing
ContactFeedback
AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions
momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks
PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12
Delisting riskPopularity #4,224
FLNA · NASDAQ · Biotechnology

Filana Therapeutics (FLNA)

FLNA

Developing simufilam, an oral small molecule, for TSC-related epilepsy.

$0.9980
After-hours close−0.03 (−3.11%)
At close$1.03(+39.28%)
OverviewEarningsFinancialsOwnershipNews

News type

  1. Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

    Benzinga8h ago

  2. Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

    GlobeNewsWire13h ago

  3. Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

    GuruFocusAug 12

  4. Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

    PRNewsWireAug 12

  5. Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

    GlobeNewsWireJul 29

  6. Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

    GlobeNewsWireMay 7

  7. Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

    GlobeNewsWireMay 5

β 1.24briefsthe tapeclosesdividendstranscriptswiresliquidityclosesminutesYoY +18%threadsTSLAthreadsthreadsmarginsafter-hrstranscriptsmomentumVIX 14.2minutesrumorsupgradesQ3estimatesnewsflowbuybacksPCEthreadsvolatility13Fnarrativesflowsmomentumdowngradesyield curvesDXYdowngradessessions52w hiheadlinesyield curvesdowngradessentimentvolatilityyield curvesrumorsβ 1.24volumesfuturesforecaststickerspre-mktforecastschatterliquidityEPS 4.12newsflownoisedrawdownsGOOGLupgradesconsensuswires8-KliquidityconsensuswhispersMSFTheadlinespositioningbriefsthreadsEPS 4.12guidanceminutesnewsflow+0.8%cyclesestimates+2.41%marginsmarginsthreads2s10sliquiditycyclesnarrativesrumorsbuybacksvolumesPMI 52.1cycleschatter2s10stranscriptsconsensusmargins
GDPclosesYoY +18%buybacksnewsflow13FrevisionsflowsT+1positioningrevisionsnewsflowconsensusvolumesfilingsAAPLfuturesYoY +18%futuresmarginsflowsvolatilityrevisionsDXYwhispersearnings callspositioningAVGOcatalystsyield curvesMETA10-Kconsensus
P/E 28.4catalystsspx 0dtecatalystsbid/askvolatilityheadlinesguidancedrawdowns
Stockpolly
An agent-based financial analysis engine for public markets.
© 2026 Stockpolly. All rights reserved.
Company
AboutPricing
Legal
TermsPrivacy
Support
ContactFeedback